Benign and malignant bone tumors are relatively rare. Benign bone tumors comprise a wide variety of different histological types^[@R1]^, occur most frequently between the ages 5 and 25 years, and can occur in any part of the skeletal system^[@R2]^. They usually do not affect life expectancy, but several histological types of intermediate bone tumors such as osteochondromatosis and giant cell tumor of bone have a risk of malignancy. The information on the characteristics of benign bone tumors that has been reported to date is disjointed, and a long-term trend of benign bone tumors by histological type has not been reported in Japan. The Swedish Cancer Registry reported a longitudinal incidence rate of giant cell tumor^[@R3]^. Conversely, the characteristics of malignant bone tumors are well known^[@R4]-[@R6]^. Such tumors occur frequently in teenagers and constitute 3% to 4% of childhood cancer in Hiroshima and all of Japan^[@R7],[@R8]^. Recently, an increased proportion of elderly patients with osteosarcoma has been reported in Japan^[@R6]^.

The goal of the present study was to describe the characteristics of bone tumors according to behavior and histological type on the basis of surgical resection and biopsy procedures that were registered in the Hiroshima Tumor Tissue Registry from 1973 to 2012.

Materials and Methods {#s1}
=====================

The Hiroshima Tumor Tissue Registry is a population-based pathological tissue registry that was initiated in 1973 by the Hiroshima Prefecture Medical Association with the cooperation of the Radiation Effects Research Foundation. It encompasses the entire Hiroshima Prefecture (population in 2012, 2.86 million, representing 2.6% of the Japanese population) in Japan. Pathologists voluntarily report the pathological diagnosis of all tumors and provide sample slides of resected malignant tumors, including biopsy specimens. When there are multiple tumor records for the same patient, such as biopsy and surgery records, the pathologist panels decide whether the records are reports of the same primary tumor or of multiple primary tumors by examining pathological reports or by performing a histological examination, if necessary. All tumors are coded with use of the first, second, or third revision of the International Classification of Diseases for Oncology (ICD-O). The Hiroshima Tumor Tissue Registry has provided all data on malignant tumors to the Hiroshima Prefecture Cancer Registry, which is a population-based cancer registry, and the Hiroshima Tumor Tissue Registry has contributed to improving the Hiroshima Prefecture Cancer Registry data quality since its inception in 2002. Details have been described elsewhere^[@R9]^.

The subjects in the present study were patients who were diagnosed with primary bone tumors of all types that were registered in the Hiroshima Tumor Tissue Registry from 1973 to 2012. Cases were identified with the ICD-O-3 topography code C40-C41 (bones, joints, and articular cartilage) and were assigned as bone tumors according to the World Health Organization (WHO) 2013 classification system^[@R10]^. Hematopoietic tumors, including malignant lymphoma, were excluded. Histological types were classified according to the WHO 2013 system^[@R10]^ (Table I). When there was uncertainty about whether the behavior was benign or malignant (ICD-O-3 behavior code, 1), as in cases of osteochondromatosis and giant cell tumor, the tumor was classified as intermediate according to the WHO 2013 system. Malignant fibrous histiocytoma has been classified as a miscellaneous tumor since 2013; however, we classified it as a fibrohistiocytic tumor in the present study. We described the number, registration rate (per million population, standardized by age-class of the Segi's World Standard Population), and proportion of bone tumor cases by behavior, sex, skeletal site of tumor occurrence, histological type, period at diagnosis (in 10-year groups), and age of diagnosis (in 10-year groups). Bone tumor skeletal sites were classified according to the ICD-O-3 topography code. The present study was approved by the Data Usage Committee of the Hiroshima Tumor Tissue Registry.

###### 

Number of Bone Tumor Cases by Behavior and Histological Type as Recorded in Hiroshima Tumor Tissue Registry, 1973-2012[\*](#tblfn1){ref-type="table-fn"}

  Histological Group[†](#tblfn2){ref-type="table-fn"}   Benign                      Intermediate                                                                     Malignant                                                                                                                                                                                                                      
  ----------------------------------------------------- --------------------------- -------------------------------------------------------------------------------- ----------- --------------------------------------- ------------------------------- -------- --------------------------------- ----------------------------------------------------------------------------------------------- -----
  1\. Chondrogenic tumors                                                                                                                                                                                                                                                                                                                                                                           
                                                        9210/0                      Osteochondroma                                                                   1,057       9210/1                                  Osteochondromatosis, NOS        40       9220/3                            Chondrosarcoma, NOS; Conventional chondrosarcoma (grade 2, grade 3); Secondary chondrosarcoma   124
                                                        9220/0                      Chondroma, NOS; enchondroma; synovial chondromatosis                             952         9220/1                                  Multiple chondromatosis         3        9221/3                            Periosteal chondrosarcoma (juxtacortical chondrosarcoma)                                        1
                                                        9221/0                      Periosteal chondroma                                                             19                                                                                           9231/3                            Myxoid chondrosarcoma                                                                           3
                                                        9230/0                      Chondroblastoma, NOS[‡](#tblfn3){ref-type="table-fn"}                            23                                                                                           9243/3                            Dedifferentiated chondrosarcoma                                                                 2
                                                        9241/0                      Chondromyxoid fibroma                                                            23                                                                                           9240/3                            Mesenchymal chondrosarcoma                                                                      4
  2\. Osteogenic tumors                                                                                                                                                                                                                                           9242/3                            Clear cell chondrosarcoma                                                                       1
                                                        9180/0                      Osteoma, NOS                                                                     254         9200/1                                  Aggressive osteoblastoma        1        9180/3                            Osteosarcoma                                                                                    176
                                                        9191/0                      Osteoid osteoma                                                                  83                                                                                                                             Osteoblastic osteosarcoma                                                                       
                                                        9200/0                      Osteoblastoma                                                                    18                                                                                           9181/3                            Chondroblastic osteosarcoma                                                                     7
                                                                                                                                                                                                                                                                  9182/3                            Fibroblastic osteosarcoma                                                                       4
                                                                                                                                                                                                                                                                  9183/3                            Telangiectatic osteosarcoma                                                                     6
                                                                                                                                                                                                                                                                  9185/3                            Small cell osteosarcoma (round-cell osteosarcoma)                                               1
                                                                                                                                                                                                                                                                  9192/3                            Parosteal osteosarcoma                                                                          7
  3\. Fibrogenic tumors                                                                                                                                                                                                                                                                                                                                                                             
                                                        8810/0                      Fibroma, NOS                                                                     13          8821/1                                  Aggressive fibromatosis         1        8810/3                            Fibrosarcoma                                                                                    4
  8823/0                                                Desmoplastic fibroma        2                                                                                                                                                                                                                                                                                                               
  4\. Fibrohistiocytic tumors                                                                                                                                                                                                                                                                                                                                                                       
                                                        8830/0                      Benign fibrous histiocytoma/non-ossifying fibroma (metaphyseal fibrous defect)   10          8823/1                                  Desmoplastic fibroma of bone    7        8830/3                            Malignant fibrous histiocytoma                                                                  33
                                                        8831/0                      Histiocytoma, NOS                                                                2           8830/1                                  Atypical fibrous histiocytoma   3                                                                                                                                          
  5\. Hematopoietic tumors                                                                                                                                                                                                                                                                                                                                                                          
  6\. Osteoclastic giant cell rich tumors                                                                                                                                        9250/1                                  Giant cell tumor of bone        212      9250/3                            Malignancy in giant cell tumor of bone                                                          14
  7\. Notochordal tumors                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                  9370/3                            Chordoma                                                                                        43
                                                                                                                                                                                                                                                                  9371/3                            Chondroid chordoma                                                                              4
  8\. Vascular tumors                                                                                                                                                                                                                                                                                                                                                                               
                                                        9120/0                      Hemangioma, NOS                                                                  16          9130/1                                  Hemangioendothelioma, NOS       2        9120/3                            Angiosarcoma                                                                                    7
  9121/0                                                Cavernous hemangioma        14                                                                               9133/1      Epithelioid hemangioendothelioma, NOS   1                               9130/3   Hemangioendothelioma, malignant   1                                                                                               
  9122/0                                                Venous hemangioma           2                                                                                9136/1      Spindle cell hemangioendothelioma       1                                                                                                                                                                          
  9131/0                                                Capillary hemangioma        6                                                                                                                                                                                                                                                                                                               
  9\. Myogenic tumors                                   8890/0                      Leiomyoma of bone                                                                1                                                                                            8890/3                            Leiomyosarcoma of bone                                                                          4
  10\. Lipogenic tumors                                                                                                                                                                                                                                                                                                                                                                             
                                                        8850/0                      Lipoma of bone                                                                   11                                                                                                                                                                                                                             
  8861/0                                                Angiolipoma, NOS            1                                                                                                                                                                                                                                                                                                               
  11\. Tumors of undefined neoplastic nature                                                                                                                                                                                                                                                                                                                                                        
                                                        8811/0                      Fibromyxoma                                                                      2                                                                                            9040/3                            Synovial sarcoma, NOS                                                                           7
                                                        8840/0                      Myxoma, NOS                                                                      1                                                                                            9041/3                            Synovial sarcoma, spindle cell                                                                  1
                                                        9262/0                      Ossifying fibroma                                                                28                                                                                           9043/3                            Synovial sarcoma, biphasic                                                                      1
  12\. Miscellaneous tumors                                                                                                                                                                                                                                                                                                                                                                         
                                                        8711/0                      Glomus tumor, NOS                                                                1           9150/1                                  Hemangiopericytoma, NOS         1        8800/3                            Sarcoma, NOS                                                                                    21
  8800/0                                                Soft tissue tumor, benign   1                                                                                                                                                                    8801/3   Spindle cell sarcoma              1                                                                                               
  8824/0                                                Myofibroma                  1                                                                                                                                                                    9260/3   Ewing sarcoma                     25                                                                                              
  9530/0                                                Meningioma, NOS             1                                                                                                                                                                    9261/3   Adamantinoma of long bones        4                                                                                               
  13\. Other rare tumors                                                                                                                                                                                                                                                                                                                                                                            
  14\. Unclassified tumors                                                                                                                                                                                                                                                                                                                                                                          
  Total                                                                                                                                                              2,542                                                                               272                                                                                                                                        506

ICD-O-3-M = International Classification of Diseases for Oncology morphology code, NOS = not otherwise specified.

The histological group was based on the WHO 2013 classification.

Chondroblastoma is regarded as demonstrating intermediate behavior according to the WHO 2013 classification; however, it is included as a benign tumor here because its ICD-O-3 behavior code is 0.

Results {#s2}
=======

Benign Bone Tumors {#s2-1}
------------------

We observed 2,542 benign bone tumors over a period of 40 years. Most benign tumors occurred in 3 sites, such as short bones of the upper limb (33.8%), long bones of the lower limb (26.8%), and short bones of the lower limb (14.3%) (Table II). The registration rates for benign bone tumors at the first period were 18.4 for males and 14.8 for females; thereafter, the rates increased and became stable around 28 for males and around 26 for females (Table III).

###### 

Number of Bone Tumor Cases by Behavior, Sex, and Skeletal Site as Recorded in Hiroshima Tumor Tissue Registry, 1973-2012[\*](#tblfn4){ref-type="table-fn"}

  Skeletal Sites (ICD-O-3-T)                                   Benign         Intermediate   Malignant                                                                         
  ------------------------------------------------------------ -------------- -------------- -------------- ------------ ------------ ------------- ------------- ------------ -------------
  C40.0: Long bones of upper limb, scapula                     98 (7.8%)      66 (5.1%)      164 (6.5%)     13 (8.9%)    10 (7.9%)    23 (8.5%)     22 (7.7%)     16 (7.3%)    38 (7.5%)
  C40.1: Short bones of upper limb                             387 (30.7%)    473 (36.9%)    860 (33.8%)    3 (2.1%)     10 (7.9%)    13 (4.8%)     2 (0.7%)      3 (1.4%)     5 (1.0%)
  C40.2: Long bones of lower limb                              369 (29.3%)    312 (24.3%)    681 (26.8%)    95 (65.1%)   69 (54.8%)   164 (60.3%)   126 (43.9%)   85 (38.8%)   211 (41.7%)
  C40.3: Short bones of lower limb                             192 (15.3%)    171 (13.3%)    363 (14.3%)    8 (5.5%)     7 (5.6%)     15 (5.5%)     5 (1.7%)      4 (1.8%)     9 (1.8%)
  C40.9: Bone of limb, NOS[\*](#tblfn4){ref-type="table-fn"}   6 (0.5%)       6 (0.5%)       12 (0.5%)      1 (0.7%)     2 (1.6%)     3 (1.1%)      1 (0.3%)      1 (0.5%)     2 (0.4%)
  C41.0: Bones of skull and face                               84 (6.7%)      137 (10.7%)    221 (8.7%)     2 (1.4%)     3 (2.4%)     5 (1.8%)      29 (10.1%)    25 (11.4%)   54 (10.7%)
  C41.1: Mandible                                              19 (1.5%)      54 (4.2%)      73 (2.9%)      0 (0%)       2 (1.6%)     2 (0.7%)      12 (4.2%)     15 (6.8%)    27 (5.3%)
  C41.2: Vertebral column                                      29 (2.3%)      21 (1.6%)      50 (2.0%)      4 (2.7%)     5 (4.0%)     9 (3.3%)      18 (6.3%)     14 (6.4%)    32 (6.3%)
  C41.3: Rib, sternum, and clavicle                            39 (3.1%)      29 (2.3%)      68 (2.7%)      3 (2.1%)     6 (4.8%)     9 (3.3%)      17 (5.9%)     22 (10.0%)   39 (7.7%)
  C41.4: Pelvic bones, sacrum, and coccyx                      29 (2.3%)      11 (0.9%)      40 (1.6%)      7 (4.8%)     10 (7.9%)    17 (6.3%)     48 (16.7%)    34 (15.5%)   82 (16.2%)
  C41.9: Bone, NOS                                             7 (0.6%)       3 (0.2%)       10 (0.4%)      10 (6.8%)    2 (1.6%)     12 (4.4%)     7 (2.4%)      0 (0%)       7 (1.4%)
  Total                                                        1,259 (100%)   1,283 (100%)   2,542 (100%)   146 (100%)   126 (100%)   272 (100%)    287 (100%)    219 (100%)   506 (100%)

All skeletal sites include associated joints except for "mandible" and "vertebral column." The values are given as the number of tumors, with the percentage in parentheses. ICD-O-3-T = International Classification of Diseases for Oncology topography code, and NOS = not otherwise specified.

###### 

Number and Registration Rates of Bone Tumors by Behavior, Histological Type, Sex, and Period at Diagnosis as Recorded in the Hiroshima Tumor Tissue Registry, 1973-2012[\*](#tblfn5){ref-type="table-fn"}

                                               Male          Female   Total                                                                                                                                                                                            
  -------------------------------------------- ------------- -------- ------------- ------ ------------- ------ ------------- ------ --------------- ------ ------------- ------ ------------- ------ ------------- ------ ------------- ------ --------------- ------ ---------------
  Benign                                                                                                                                                                                                                                                               
   1. Chondrogenic tumors                      198 (85.0%)   15.7     323 (86.6%)   24.4   283 (82.7%)   24.1   252 (81.0%)   24.0   1,056 (83.9%)   21.7   159 (81.1%)   12.2   295 (81.9%)   20.8   298 (78.4%)   22.3   266 (76.7%)   21.4   1,018 (79.3%)   19.1   2,074 (81.6%)
   2. Osteogenic tumors                        24 (10.3%)    1.9      38 (10.2%)    2.7    46 (13.5%)    3.4    44 (14.1%)    3.9    152 (12.1%)     3.0    24 (12.2%)    1.7    45 (12.5%)    2.9    64 (16.8%)    3.5    70 (20.2%)    4.2    203 (15.8%)     3.1    355 (14.0%)
   3. Fibrogenic tumors                        1 (0.4%)      0.1      3 (0.8%)      0.2    4 (1.2%)      0.4    1 (0.3%)      0.1    9 (0.7%)        0.2    1 (0.5%)      0.1    1 (0.3%)      0.1    2 (0.5%)      0.1    2 (0.6%)      0.1    6 (0.5%)        0.1    15 (0.6%)
   4. Fibrohistiocytic tumors                  1 (0.4%)      0.1      1 (0.3%)      0.1                                              2 (0.2%)        0.0    2 (1.0%)      0.2    4 (1.1%)      0.3    3 (0.8%)      0.2    1 (0.3%)      0.0    10 (0.8%)       0.2    12 (0.5%)
   8. Vascular tumors                          5 (2.1%)      0.3      3 (0.8%)      0.2    4 (1.2%)      0.2    7 (2.3%)      0.4    19 (1.5%)       0.3    3 (1.5%)      0.2    7 (1.9%)      0.4    4 (1.1%)      0.2    5 (1.4%)      0.2    19 (1.5%)       0.3    38 (1.5%)
   9. Myogenic tumors                                                                                           1 (0.3%)      0.2    1 (0.1%)        0.0                                                                                                               1 (0.0%)
   10. Lipogenic tumors                        1 (0.4%)      0.1      1 (0.3%)      0.1    2 (0.6%)      0.1    1 (0.3%)      0.1    5 (0.4%)        0.1    1 (0.5%)      0.1    1 (0.3%)      0.1    4 (1.1%)      0.2    1 (0.3%)      0.0    7 (0.5%)        0.1    12 (0.5%)
   11. Tumors of undefined neoplastic nature   3 (1.3%)      0.2      4 (1.1%)      0.3    1 (0.3%)      0.1    3 (1.0%)      0.2    11 (0.9%)       0.2    6 (3.1%)      0.4    7 (1.9%)      0.6    5 (1.3%)      0.3    2 (0.6%)      0.1    20 (1.6%)       0.4    31 (1.2%)
   12. Miscellaneous tumors                                                                2 (0.6%)      0.1    2 (0.6%)      0.2    4 (0.3%)        0.1                                                                                                               4 (0.2%)
   Subtotal                                    233 (100%)    18.4     373 (100%)    27.9   342 (100%)    28.5   311 (100%)    29.1   1,259 (100%)    25.6   196 (100%)    14.8   360 (100%)    25.1   380 (100%)    26.9   347 (100%)    26.2   1,283 (100%)    23.3   2,542 (100%)
  Intermediate                                                                                                                                                                                                                                                         
   1. Chondrogenic tumors                      1 (2.6%)      0.1      5 (20.0%)     0.5    13 (33.3%)    1.4    5 (11.4%)     0.6    24 (16.4%)      0.6                         4 (16.0%)     0.3    10 (27.8%)    0.9    5 (14.7%)     0.5    19 (15.1%)      0.4    43 (15.8%)
   2. Osteogenic tumors                                                                                         1 (2.3%)      0.0    1 (0.7%)        0.0                                                                                                               1 (0.4%)
   3. Fibrogenic tumors                                                                    1 (2.6%)      0.1                         1 (0.7%)        0.0                                                                                                               1 (0.4%)
   4. Fibrohistiocytic tumors                  1 (2.6%)      0.1      3 (12.0%)     0.2    1 (2.6%)      0.0                         5 (3.4%)        0.1                         4 (16.0%)     0.3    1 (2.8%)      0.1                         5 (4.0%)        0.1    10 (3.7%)
   6. Osteoclastic giant cell rich tumors      35 (92.1%)    2.7      17 (68.0%)    1.3    22 (56.4%)    1.5    38 (86.4%)    2.8    112 (76.7%)     2.1    31 (100%)     2.2    17 (68.0%)    1.1    24 (66.7%)    1.7    28 (82.4%)    2.1    100 (79.4%)     1.8    212 (77.9%)
   8. Vascular tumors                                                                      2 (5.1%)      0.2                         2 (1.4%)        0.0                                              1 (2.8%)      0.1    1 (2.9%)      0.1    2 (1.6%)        0.0    4 (1.5%)
   12. Miscellaneous tumors                    1 (2.6%)      0.1                                                                     1 (0.7%)        0.0                                                                                                               1 (0.4%)
   Subtotal                                    38 (100%)     2.9      25 (100%)     1.9    39 (100%)     3.3    44 (100%)     3.5    146 (100%)      2.9    31 (100%)     2.2    25 (100%)     1.7    36 (100%)     2.7    34 (100%)     2.7    126 (100%)      2.3    272 (100%)
  Malignant                                                                                                                                                                                                                                                            
   1. Chondrogenic tumors                      6 (13.3%)     0.4      27 (31.8%)    1.6    17 (23.3%)    0.9    22 (26.2%)    1.0    72 (25.1%)      1.1    16 (36.4%)    1.1    16 (34.0%)    0.9    13 (25.0%)    0.6    18 (23.7%)    0.9    63 (28.8%)      0.9    135 (26.7%)
   2. Osteogenic tumors                        23 (51.1%)    1.9      33 (38.8%)    2.5    31 (42.5%)    2.3    27 (32.1%)    2.5    114 (39.7%)     2.3    13 (29.5%)    0.9    20 (42.6%)    1.4    26 (50.0%)    1.8    28 (36.8%)    2.6    87 (39.7%)      1.6    201 (39.7%)
   3. Fibrogenic tumors                                               1 (1.2%)      0.1    1 (1.4%)      0.0                         2 (0.7%)        0.0    1 (2.3%)      0.1                                              1 (1.3%)      0.0    2 (0.9%)        0.0    4 (0.8%)
   4. Fibrohistiocytic tumors                  2 (4.4%)      0.2      2 (2.4%)      0.1    12 (16.4%)    0.6    7 (8.3%)      0.2    23 (8.0%)       0.3    2 (4.5%)      0.1                         2 (3.8%)      0.1    6 (7.9%)      0.3    10 (4.6%)       0.1    33 (6.5%)
   6. Osteoclastic giant cell rich tumors      2 (4.4%)      0.1      6 (7.1%)      0.4                                              8 (2.8%)        0.1    2 (4.5%)      0.1    4 (8.5%)      0.2                                              6 (2.7%)        0.1    14 (2.8%)
   7. Notochordal tumors                       4 (8.9%)      0.3      7 (8.2%)      0.4    5 (6.8%)      0.2    14 (16.7%)    0.5    30 (10.5%)      0.3    3 (6.8%)      0.2                         1 (1.9%)      0.0    13 (17.1%)    0.7    17 (7.8%)       0.2    47 (9.3%)
   8. Vascular tumors                                                 3 (3.5%)      0.1                         1 (1.2%)      0.0    4 (1.4%)        0.0                                              2 (3.8%)      0.1    2 (2.6%)      0.1    4 (1.8%)        0.0    8 (1.6%)
   9. Myogenic tumors                                                                      1 (1.4%)      0.1                         1 (0.3%)        0.0                                                                   3 (3.9%)      0.1    3 (1.4%)        0.0    4 (0.8%)
   11. Tumors of undefined neoplastic nature   3 (6.7%)      0.2      2 (2.4%)      0.1                                              5 (1.7%)        0.1    2 (4.5%)      0.1                         2 (3.8%)      0.1                         4 (1.8%)        0.1    9 (1.8%)
   12. Miscellaneous tumors                    5 (11.1%)     0.4      4 (4.7%)      0.3    6 (8.2%)      0.4    13 (15.5%)    1.2    28 (9.8%)       0.5    5 (11.4%)     0.4    7 (14.9%)     0.6    6 (11.5%)     0.5    5 (6.6%)      0.2    23 (10.5%)      0.4    51 (10.1%)
   Subtotal                                    45 (100%)     3.5      85 (100%)     5.6    73 (100%)     4.6    84 (100%)     5.5    287 (100%)      4.9    44 (100%)     3.0    47 (100%)     3.1    52 (100%)     3.2    76 (100%)     4.8    219 (100%)      3.5    506 (100%)
  Total                                        316                    483                  454                  439                  1,692                  271                  432                  468                  457                  1,628                  3,320

The values in the "Rate" columns indicate the age-standardized registration rate per million population according to the Segi's World Standard Population. Patients whose age was unknown were excluded.

Among the benign tumors, the most common histological type was chondrogenic tumors (2,074; 81.6%) and the distribution of histological types was uniform and similar for both sexes for the entire observation period (Table III). A primary peak for benign chondrogenic tumors occurred in patients 10 to 19 years of age and then rapidly decreased. Thereafter, the number of patients \>20 years of age gradually decreased among men, whereas a secondary peak in patients 30 to 49 years of age was observed in women (Fig. [1](#F1){ref-type="fig"}).

![Line graphs illustrating the age distribution for major histological groups of bone tumors by sex and behavior as recorded in the Hiroshima Tumor Tissue Registry between 1973 and 2012.](jbjsoa-3-00e0064-g001){#F1}

Among benign chondrogenic tumors, there were 1,057 osteochondromas (51.0%, ICD-O-3-M (morphology code)/behavior: 9210/0) and 952 enchondromas (45.9%, ICD-O-3-M/behavior: 9220/0). The number of osteochondromas peaked in teenagers for both sexes, whereas the number of enchondromas peaked in patients 30 to 49 years of age for both sexes (Fig. [2](#F2){ref-type="fig"}). Therefore, a secondary peak of benign chondrogenic tumors in patients 30 to 49 years of age among women was due to the peak of enchondroma. The peak of enchondroma in patients 30 to 49 years of age among women was enhanced compared with men, because the peak of osteochondroma in teenagers among females was relatively lower than that among males. Regarding the skeletal sites, osteochondromas occurred frequently in the lower limbs (long bones, 46.7%; short bones, 19.1%), whereas enchondromas occurred frequently in the short bones of the upper limbs (70.8%) (Fig. [3](#F3){ref-type="fig"}). Tumor distributions by skeletal site for osteochondroma and enchondroma were similar for both sexes.

![Line graphs illustrating the age distribution for osteochondroma and enchondroma in patients with benign chondrogenic tumors as recorded in the Hiroshima Tumor Tissue Registry between 1973 and 2012.](jbjsoa-3-00e0064-g002){#F2}

![Diagrams illustrating the skeletal site distribution for bone tumors by behavior and histological group as recorded in the Hiroshima Tumor Tissue Registry between 1973 and 2012.](jbjsoa-3-00e0064-g003){#F3}

Benign osteogenic tumors were the second most common benign tumor (355; 14.0%) (Table III) and occurred in the skull and face (48.5%) as well as mandible (14.9%) (Fig. [3](#F3){ref-type="fig"}). The number of patients with osteogenic tumors peaked at 10 to 19 years of age for both males and females, with an apparent secondary peak at 50 to 59 years of age among women (Fig. [1](#F1){ref-type="fig"}).

Intermediate Bone Tumors {#s2-2}
------------------------

We observed 272 intermediate bone tumors, including 212 giant cell tumors (77.9%) and 43 chondrogenic tumors (osteochondromatosis) (15.8%). The registration rates for intermediate bone tumors were 2.9 for males and 2.3 for females and remained stable over the observation periods (Table III). A primary peak of giant cell tumor was seen in patients 20 to 29 years of age, whereas a secondary peak was observed in patients 50 to 59 years of age (Fig. [1](#F1){ref-type="fig"}). Among the giant cell tumors, 64.6% of cases occurred in the long bones of the lower limb (Fig. [3](#F3){ref-type="fig"}).

Malignant Bone Tumors {#s2-3}
---------------------

We observed 506 malignant bone tumors over a period of 40 years. The registration rates from the first to the fourth decade were 3.5, 5.6, 4.6, and 5.5 for males and 3.0, 3.1, 3.2, and 4.8 for females, respectively (Table III). Malignant bone tumors occurred in the long bones of the lower limb (41.7%); in the pelvis, sacrum, and coccyx (16.2%); in the skull and face (10.7%); and in the rib, sternum, and clavicle (7.7%) (Table II). The numbers of malignant bone tumors were 287 for males and 219 for females, and the male:female ratio was 1.31:1. A primary peak in malignant bone tumors occurred in patients 10 to 19 years of age and then rapidly decreased. A plateau was observed in patients 20 to 50 years of age, with a secondary peak observed for patients 60 to 69 years of age and a decline observed in elderly individuals.

Tumor distributions by age were similar for both sexes. Among malignant bone tumors, the most frequent tumor types were osteogenic tumors (201; 39.7%) and chondrogenic tumors (135; 26.7%) (Table III). These 2 major histological groups covered approximately two-thirds of all malignant bone tumors. There was only a peak in teens for malignant osteogenic tumors, which occurred in the long bones of the lower limb (58.7%) (Figs. [1](#F1){ref-type="fig"} and [3](#F3){ref-type="fig"}). There was a primary peak in teenagers and a secondary peak in middle-aged patients for malignant chondrogenic tumors, which were distributed in the long bones of lower limb (25.9%); in the bones of the trunk of the body such as the rib, sternum, and clavicle (20.0%); and around the pelvis (20.0%) (Figs. [1](#F1){ref-type="fig"} and [3](#F3){ref-type="fig"}).

Time trends of the number of cases and registration rates were stable for entire period, particularly for female patients (Table III). However, in the last decade, the number of malignant cases increased because of an increase in the number of notochordal tumors in subjects aged 50 to 79 years.

Among the 51 miscellaneous tumors, 25 Ewing sarcomas were observed (14 in males and 11 in females) (Table I). Most cases of Ewing sarcoma occurred in children and adolescents (including 2 in patients 0 to 9 years of age and 13 in patients 10 to 19 years of age), and the other 10 cases occurred in patients 20 to 39 years of age.

Discussion {#s3}
==========

We presented the statistics---by sex, skeletal site, and histological type---on bone tumors of all behavior types that were diagnosed between 1973 and 2012. We confirmed that 81.6% of benign bone tumors were chondrogenic tumors, primarily consisting of osteochondromas and enchondromas. The most dominant types of malignant tumors were osteogenic tumors and chondrogenic tumors. Approximately 40% of the malignant bone tumors occurred in the long bones of the lower limb, with different age peaks at the time of diagnosis for each major histological type. A similar distribution of histological types was seen during the 40-year observation period. We observed only 25 cases of Ewing sarcoma over 40 years.

Few cancer registries routinely collect data on both benign and malignant tumors. The Bone and Soft Tissue Tumor (BSTT) Registry in Japan, which is a nationwide and organ-specific registry, collects data on both benign and malignant bone tumors^[@R6]^. A recent report from that registry^[@R11]^ demonstrated that 8,979 benign bone tumors were registered between 2006 and 2013. With the exclusion of lesions that were not recognized as benign bone tumors in the present study (i.e., giant cell tumors \[1,187\], neurilemmomas \[51\], neurofibromas \[2\], and tumors of an unknown histological type \[150\]), the number of benign bone tumors decreased to 7,589. Of those, the most dominant type was chondrogenic tumors (80.4%; 6,100 of 7,589) and the second most common type was osteogenic tumors (10.1%; 768 of 7,589). The distribution of histological types among benign tumor cases reported by the BSTT Registry was consistent with the benign tumors in the present study. The BSTT Registry also showed that a primary peak of osteochondroma occurred in teenagers and that a primary peak of enchondroma occurred among men 30 to 34 years of age and among women 35 to 44 years of age^[@R11]^. The age distributions of osteochondroma and enchondroma were in accordance with our results.

The Swedish Cancer Registry, the Bone Tumor Registry of Western Australia, and the BSTT Registry collect information on giant cell tumor, which is recognized as an intermediate tumor. Liede et al. reported that the giant cell tumor-to-osteosarcoma ratio, based on the data from the BSTT registry in Japan as well as the registries of Sweden and Mexico, ranged from 0.49 to 0.79^[@R12]^. The giant cell tumor-to-osteosarcoma ratio from the Hiroshima Tumor Tissue Registry was 1.05, which was slightly higher than that reported in other registries.

Osteochondromatosis has a risk of malignant transformation into secondary chondrosarcoma, particularly in cases with multiple exostoses^[@R13]^. We observed 43 cases of osteochondromatosis, which has been reported to have a probability of malignant transformation of 1% to 5% among all primary osteochondromas^[@R14],[@R15]^. As the patients with osteochondromatosis in the Hiroshima Tumor Tissue Registry had had tissue resected during biopsy or surgery, we carefully reviewed their data individually to determine whether there were any cases in which osteochondromatosis had transformed into malignant chondrosarcoma, but we did not find any cases of malignant transformation. We will continue to consider the possibility of malignant transformation among patients with osteochondromatosis who are registered in the Hiroshima Tumor Tissue Registry.

A peak in the incidence of osteosarcoma has been observed in elderly Caucasian individuals as a result of the relatively high prevalence of osteosarcoma in patients with Paget disease^[@R4]^. In addition, Ogura et al., in a report from the BSTT Registry, reported an increasing proportion of osteosarcoma cases among the elderly in Japan^[@R6]^. However, we found neither a peak of osteosarcoma in the elderly nor any case of osteosarcoma with Paget disease. These findings are attributed to the lower prevalence of osteosarcoma with Paget disease. Hashimoto et al.^[@R16]^, on the basis of a mail survey, reported that the prevalence of Paget disease was 2.8 per million in Japan during the period between 1990 and 2002. This prevalence was extremely low when compared with the prevalence of 0.1% to 5% among individuals in high-prevalence countries^[@R17]^. Furthermore, Hashimoto et al. reported that half of the cases in their report were not confirmed by histological diagnosis^[@R16]^. Therefore, osteosarcoma in patients with Paget disease may not have been registered in the Hiroshima Tumor Tissue Registry.

We found that giant cell tumor represented a considerable proportion of bone tumors. Giant cell tumors primarily appeared in the long bones of the lower limb in patients 10 to 40 years of age. Giant cell tumor previously was considered to be benign, but recurrence after excision has been reported in 20% to 50% of patients, with 10% of cases becoming malignant upon recurrence^[@R18],[@R19]^. Histologically benign giant cell tumor rarely occurs in cases of lung metastases^[@R20]^. Therefore, giant cell tumor has been classified as intermediate since the latest WHO 2013 classification^[@R10]^. Although the first choice of treatment is curettage followed by filling with bone cement^[@R21],[@R22]^ and additional treatment with adjuvants, the rate of recurrence is still high^[@R1],[@R18]^. Chemotherapy with denosumab, a monoclonal antibody that inhibits the osteoclastic activity of giant cell tumor, recently has emerged as another choice of treatment^[@R21]^. Active treatments are necessary in cases of giant cell tumor because of the risk of recurrence and malignant metastasis; however, the safety of long-term denosumab use has not yet been reported^[@R23]^, although it was approved for use in giant cell tumor treatment in Japan in May 2014^[@R24]^. We will continue to carefully observe the cases of giant cell tumor and the associated characteristics.

The present study had several limitations. First, our data were based on patients with tumors that had been resected during surgery or biopsy and registered in the Hiroshima Tumor Tissue Registry. Patients who did not undergo therapeutic or diagnostic resection were not registered in the database. According to *Cancer Incidence in Five Continents,* the incidence of malignant bone tumors in Hiroshima City from 1978 to 1999 and the rate in Hiroshima Prefecture per 100,000 population in the period 2003 to 2007 were reported to be 0.5 to 0.8 for males and 0.4 to 0.6 for females^[@R9],[@R25]-[@R29]^; in comparison, the registration rates per 100,000 population for malignant bone tumor in the Hiroshima Tumor Tissue Registry were 0.35 to 0.56 for males and 0.30 to 0.48 for females. Second, we observed 2,542 benign bone tumors over a period of 40 years; however, this number is most likely an underestimation because the majority of benign bone tumors are asymptomatic^[@R30]^ and are not usually detected or resected for diagnosis. Conventional radiology such as radiographs, computed tomography, and magnetic resonance imaging are used to diagnose chondroid tumors^[@R1]^. Among the benign bone tumors registered in the Hiroshima Tumor Tissue Registry and diagnosed after 1993, 95.6% were in patients who underwent surgery.

The Hiroshima Tumor Tissue Registry is a population-based tumor tissue registry that collects information on all tumors that are diagnosed pathologically in hospitals and clinical laboratories in Hiroshima Prefecture. In 2012, 88 institutions, including all designated cancer care hospitals, hospitals, clinics, and clinical laboratories, reported their tumor diagnoses to the Hiroshima Tumor Tissue Registry. Of the cancer cases registered in the Hiroshima Prefecture Cancer Registry, which is a regional cancer registry, 75% of the cases were also covered by the Hiroshima Tumor Tissue Registry^[@R31]^. Moreover, at the time of registration, all patients reported by local pathologists to the Hiroshima Tumor Tissue Registry are confirmed to not already be registered in the database with use of personal identifying information such as name, date of birth, address, etc. Therefore, there is no duplication of patients, even if the tumor information is reported by different hospitals (e.g., following biopsy and surgical diagnosis). The diagnoses associated with all tumors registered in the Hiroshima Tumor Tissue Registry are confirmed histologically. If a patient with a benign bone tumor needed medical treatment, the diagnosis should be confirmed pathologically and the tumor information is registered in the Hiroshima Tumor Tissue Registry. Despite these limitations, we believe that the information on all benign, intermediate, and malignant bone tumors in the present study is valuable, and we have been able to show the variation of histological type and age distribution of bone tumors by behavior in Hiroshima Prefecture.

This report described characteristics of benign, intermediate, and malignant bone tumors with regard to frequency of cases, registration rate, age distribution, and skeletal site by pathological type. There were differences between osteochondroma and enchondroma in terms of the number of patients and skeletal sites where the tumor most frequently occurred, although both tumor types were originated from chondrogenic tumors. Giant cell tumor has a high frequency and was the most dominant type of intermediate bone tumor. These findings shed light on the epidemiological and pathological features of bone tumors.
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